Hong Kong: Regencell Bioscience closes Nasdaq IPO to raise US$21.9m

Regencell Bioscience Holdings, an early-stage bioscience company that focuses on traditional Chinese medicine for the treatment of neurocognitive disorders and degeneration, has closed its IPO of 2,300,000 ordinary shares at US$9.50 per share. The company received aggregate gross proceeds of US$21.9m. Proceeds will be used to fund research studies, as well as general corporate purposes….

You must be a HMI Subscriber to view this content.

Subscribe Now »